DMAC
DiaMedica Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$332.99M
P/E Ratio
—
EPS
$-0.70
Beta
1.15
52W High
$10.42
52W Low
$3.48
50-Day MA
$7.00
200-Day MA
$7.04
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-34.35M |
| Operating Margin | 0.00% |
| Return on Equity | -67.70% |
| Return on Assets | -39.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.04 |
| Price-to-Book | 5.80 |
| Price-to-Sales (TTM) | 66.68 |
| EV/Revenue | 57.48 |
| EV/EBITDA | -0.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.88M |
| Float | $28.43M |
| % Insiders | 27.74% |
| % Institutions | 38.42% |
Historical Volatility
HV 10-Day
44.01%
HV 20-Day
46.64%
HV 30-Day
51.05%
HV 60-Day
48.24%
HV Rank
27.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
5
BuyMore HEALTHCARE Stocks
Data last updated: 5/2/2026